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Abstract: There have been large numbers of studies on anti-HEV IgG seroprevalence in Europe,
however, the results of these studies have produced high variability of seroprevalence rates, making
interpretation increasingly problematic. Therefore, the aim of this study was to develop a clearer
understanding of anti-HEV IgG seroprevalence in Europe and identify risk groups for HEV exposure
by a meta-analysis of published studies. Methods: All European HEV-seroprevalence studies from
2003 to 2015 were reviewed. Data were stratified by assay, geographical location, and patient
cohort (general population, patients with HIV, solid-organ transplant recipients, chronic liver disease
patients, and individuals in contact with swine/wild animals). Data were pooled using a mixed-effects
model. Results: Four hundred thirty-two studies were initially identified, of which 73 studies were
included in the analysis. Seroprevalence estimates ranged from 0.6% to 52.5%, increased with age,
but were unrelated to gender. General population seroprevalence varied depending on assays:
Wantai (WT): 17%, Mikrogen (MG): 10%, MP-diagnostics (MP): 7%, DiaPro: 4%, Abbott 2%. The WT
assay reported significantly higher seroprevalence rates across all cohorts (p < 0.001). Individuals
in contact with swine/wild animals had significantly higher seroprevalence rates than the general
population, irrespective of assay (p < 0.0001). There was no difference between any other cohorts.
The highest seroprevalence was observed in France (WT: 32%, MP: 16%) the lowest in Italy (WT: 7.5%,
MP 0.9%). Seroprevalence varied between and within countries. The observed heterogeneity was
attributed to geographical region (23%), assay employed (23%) and study cohort (7%). Conclusion:
Seroprevalcence rates primarily depend on the seroassy that is used, followed by the geographical
region and study cohort. Seroprevalence is higher in individuals exposed to swine and/or wild
animals, and increases with age.
Keywords: hepatitis E; serosurvey; seroprevalence; Europe; developing countries; genotype 3; assay;
anti-HEV IgG
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1. Introduction
Hepatitis E virus (HEV) is hyperendemic in many developing countries, especially in Southeast
Asia and Africa, where it causes acute hepatitis predominantly in young adults. Hepatitis E is usually
an acute self-limiting illness, except in pregnant women and patients with underlying chronic liver
disease, who have mortality rates of up to 25% and 70%, respectively [1]. The disease is caused by HEV
genotypes 1 and 2, which are obligate human pathogens spread orofaecally via contaminated water
supplies. Cases occur both sporadically and occasionally in large outbreaks. Every year, an estimated
20 million HEV infections occur resulting in more than three million clinical cases and 70,000 deaths [2].
In developed regions, hepatitis E was previously thought to be rare and largely restricted to
travelers returning from endemic developing nations. This notion was mistaken [3]. Data published
throughout the last ten years show quite clearly that locally-acquired hepatitis E in Europe and
other developed countries is common. In contrast to imported HEV genotype 1 or 2 infections,
autochthonous hepatitis E in Europe and most developed countries is caused by genotype 3 and
features different clinical characteristics, in particular, it is largely a porcine zoonosis [4]. In addition,
chronic HEV infection occurs in the immunosuppressed. This includes transplant recipients receiving
immunosuppressive therapy [5–7], patients with haematological malignancy [8], and individuals
infected with HIV and low T CD4 count [9]. While patients with underlying chronic liver disease quite
frequently develop acute/subacute liver failure, with a mortality of 27% [10], hepatitis E in developed
countries is mostly asymptomatic [11,12]. As a result, HEV has found its way into the human blood
supply, with a surprisingly high frequency of viremic donors in some European countries [13–16].
One approach which helps our understanding of past and present infections in a community, is
the study of IgG seroprevalence. There have been a large number of anti-HEV IgG seroprevalence
studies in Europe that have been published over the last few years. The results of these studies have
been difficult to interpret, as seroprevalence estimates in Europe range from 0.6% to 52.5% [17,18] and
the wide range of results reported appear to depend on a number of variables. In particular, there
seems to be a large variability in seroprevalence estimates depending on the used anti-HEV IgG assay.
The aim of this study was to develop a clearer understanding of anti-HEV IgG seroprevalence in
Europe by a meta-analysis of published studies. In order to produce a realistic overview of anti-HEV
seroprevalence, we performed a detailed calculation of European anti-HEV-seroprevalence rates
depending on the used seroassay, the study cohort, and geographic location.
2. Methods
2.1. Search Strategy and Selection Criteria
The meta-analysis is reported in line with the guidelines of the “Preferred Reporting Items
for Systematic Reviews and Meta-Analyses” (PRISMA) [19,20]. A keyword literature search was
performed in PubMed using the terms “hepatitis E seroprevalence”, “hepatitis E serosurvey”, “hepatitis
E epidemiology”, combined with “country”, restricting the search to publication dates between January
2003 and May 2015. Studies that did not report the type of assay employed, reported seroprevalence
rates in children, or had a sample size fewer than 20 were not included. No language restrictions were
applied. Only studies regarding seroprevalence rates in countries entirely contained in continental
Europe were included (i.e., excluding Turkey and the Russian Federation). Original abstracts were
obtained and assessed in detail for inclusion. Following abstract review, the full papers of the included
studies were reviewed (Figure 1). Data were reviewed independently by two investigators (J.H. and
S.P.) and any disagreements were resolved by discussion.
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Figure 1. Search algorithm for the anti-HEV IgG seroprevalence meta-analysis.
2.2. Data Extraction
The following information was extracted from each study: first author, journal, year of publication,
country, diagnostic assay used, number of patients, seroprevalence, type of patient cohort, age, and
gender of subjects. Data were stratified for three variables: assay employed, country of study, and
nature of study-cohort. We focused on five different study-cohorts: general population/blood donors,
patients infected with HIV, solid organ transplant recipients, patients with chronic liver disease, and
individuals with contact with swine/wild animals. The latter included veterinarians, farmers, forestry
workers, and slaughterhouse workers (Figure 1). Some studies provided information for more than
one study category (e.g., a different assay was employed for one or more study cohorts), so the total
number of data points exceeded the number of studies. Supplementary Table S1 shows the number
of included studies per country, while supplementary Table S2 provides detailed information on all
included studies and data extracted from each study.
2.3. Study Quality
Primary study quality criteria which were applied were: sample size ¥ 20; identification of assay
employed and confirmation that it was used according to the manufacturer’s instructions; absence
of age restriction of the study cohort (e.g., study limited to only age > 65 years, children and/or
adolescents < 18 years were excluded); population based study. Studies that did not meet all of the
study quality criteria were excluded from the meta-analysis.
2.4. Statistical Analysis
We estimated prevalence of anti-HEV IgG by pooling the study data in order to run a meta-analysis.
We used a mixed-effects model including the assay employed, the country of study and study
cohort information as single or interacting moderators. We used the double arcsine transformation
method for variance stabilization [21] and a restricted maximum likelihood (REML) estimator for
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prevalence estimation. The analysis was conducted using the R statistical platform (version 3.1.2)
and The metafor Package (version 1.9-5) [22]. The I2 statistic was used to estimate the amount of
heterogeneity accounted for by each model [23].
3. Results
The PubMed search identified 432 publications, which were screened by title and abstract.
Ninety-two articles were considered for full text assessment and reviewed by two independent
reviewers. Seventy-three studies from 11 countries were included in the final data analysis, with
reported seroprevalence rates ranging from 0.6% to 52.5% [17,18]. These studies were composed of
a total of 129,254 individuals who were tested for anti-HEV IgG and included 116,043 individuals from
the “general population” (healthy individuals), 4964 infected with HIV, 2629 solid organ transplant
recipients, 2971 patients with chronic liver disease, and 2647 with contact with swine/wild animals.
The study flowchart is shown in Figure 1.
3.1. Anti-HEV IgG Assays Employed
The pooled anti-HEV IgG seroprevalence rates determined by different commercial assays showed
large variability with reported seroprevalence rates ranging from 2% to 17% (Table 1). The most
frequently used assays were Wantai (WT), Mikrogen (MG), and MP-diagnostics (MP). For these three
assays the pooled seroprevalence rates for the general population were: WT 17% (95% confidence
interval, 12.2%–21.2%), MG 10% (3.2%–20.4%), and MP 7% (1.9%–14.1%). For the general population
the WT assays reported significantly higher seroprevalence rates compared to MG (p < 0.05) and
MP (p < 0.01). This pattern was observed in all study cohorts (Figure 2). Nine studies assessed
seroprevalence rates in a given population by using different assays and found a large discordance
between determined seroprevalence rates (Table 2). Importantly, estimated seroprevalence rates in
these studies showed the same pattern as seen in Figure 2, with the highest seroprevalence estimated
by WT, followed by MG and MP.
Table 1. Anti-HEV IgG seroprevalence rates determined by different commercial assays for different
study cohorts.
Study cohort Wantai Mikrogen MP Abbott Adaltis Dia.Pro Others
General Population (%) 16.90 10.11 6.50 2.29 8.72 4.35 12.48
Sample size (n) 88,204 1777 14,385 1077 nd * 5,176 3667
Liver Disease (%) 16.05 9.55 6.13 2.02 8.2 3.94 11.86
Sample size (n) nd * 41 801 129 nd * nd * 2000
Transplant recipients (%) 18.36 11.42 7.69 2.97 9.96 5.22 13.91
Sample size (n) 415 124 1328 262 64 448 52
HIV (%) 15.69 9.26 5.900 1.88 7.93 3.75 11.55
Sample size (n) 2047 nd * 1579 123 429 548 238
Swine/Animal Contatct (%) 28.51 20.13 15.26 8.37 18.25 11.82 23.21
Sample size (n) 101 709 1354 202 43 nd * 995
* For combinations of seroassays and study cohorts for which reported seroprevalence rates were not determined
(nd), the seroprevalence was calculated by using a restricted maximum likelihood estimator model (R statistical
platform and The metafor Package).




Figure 2. The relationship between anti‐HEV  IgG seroprevalence rates and  the assay employed  in 
different study cohorts. The difference between Wantai (WT) vs. Mikrogen (MG) and WT vs. MP was 
statistically significant after adjusting for study cohort (WT vs. MG: p < 0.05; WT vs. MP: p < 0.001). 
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Figure 2. The relationship between anti-HEV IgG seroprevalence rates and the assay employed in
different study cohorts. The diff rence between Wantai (WT) vs. Mikrogen (MG) and WT vs. MP was
statistically significant after adjusting for study cohort ( T . G: p < 0.05; WT vs. MP: p < 0.001).
Table 2. Studies assessing anti-HEV IgG seroprevalence in a given population by different anti HEV-IgG
assays (n = 9).
Journal Year FirstAuthor
Cohort
Size Sero-PrevalenceAssay Cohort Country
Transfusion 2015 Holm 504 10.7 Other GP Denmark
Transfusion 2015 Holm 504 19.8 Wantai GP Denmark
J Clin Virol 2013 Rossi-Tamisier 64 10.9 Adaltis Tx France
J Clin Virol 2013 Rossi-Tamisier 64 31.3 Wantai Tx France
J Infect Dis 2012 Wenzel 200 18 Mikrogen GP Germany
J Infect Dis 2012 Wenzel 200 4.5 MP GP Germany
J Infect Dis 2012 Wenzel 200 29.5 Other GP Germany
Hepatology 2014 Wenzel 1092 14.5 Mikrogen GP Germany
Hepatology 2014 Wenzel 1092 34 Other GP Germany
Med Mibrobiol Immun 2014 Krumbholz 235 8.5 Mikrogen GP Germany
Med Mibrobiol Immun 2014 Krumbholz 235 2.6 MP GP Germany
Med Mibrobiol Immun 2014 Krumbholz 235 7.7 Other GP Germany
Med Mibrobiol Immun 2014 Krumbholz 302 17.9 ikrogen SW Germany
Med Mibrobiol Immun 2014 Krumbholz 302 3.5 MP SW Germany
Med Mibrobiol Immun 2014 Krumbholz 302 13.2 Other SW Germany
Epidemiol Infect 2008 Bouwknegt 644 1.7 Abbott GP Netherlands
Epidemiol Infect 2008 Bouwknegt 644 4.2 MP GP Netherlands
Epidemiol Infect 2008 Bouwknegt 49 8.1 Abbott SW Netherlands
Epidemi l Infect 2008 Bouwknegt 49 12.2 MP SW Netherlands
Epidemiol Infect 2008 Bouwknegt 153 5.2 Abbott SW Netherlands
Epidemiol Infect 2008 Bouwknegt 153 3.9 MP SW Netherlands
Transfusion 2014 Sauleda 10,000 10.72 Mikrogen GP Spain
Transfusion 2014 Sauleda 10,000 19.96 Wantai GP Spain
PL S One 2013 Schnegg 550 4.9 MP GP Switzerland
PLoS One 2013 Schnegg 550 4.2 Dia.Pro GP Switzerland
PLoS One 2013 Schnegg 550 21.2 Wantai GP Switzerland
J Med Virol 2010 Bendall 500 3.6 MP GP UK
J Med Virol 2010 Bendall 500 16.2 Wantai GP UK
GP: general popul tion; Tx: transplant recipients; SW: swine/animal contact.
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3.2. Study Cohort
Individuals with close contact to swine/wild animals had higher seroprevalence rates compared to
the other study cohorts (Figures 2 and 3B). This finding was independent of the assay used. Compared
to the general population, individuals exposed to swine/wild animals had seroprevalence rates of 17%
(12.2%–21.2%) vs. 28% (16.9%–41.7%) (p < 000.1) using WT, 10% [3.2%–20.4%] vs. 20% (5.5%–40.9%)
(p < 0.001) using MG, and 7% (1.7%–14.1%) vs. 15% (3.6%–33%) (p < 0.001) when the MP assay was
employed. We found no statistically significant difference between the seroprevalence rates between
any of the other study cohorts (Figure 3B).
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Figure 3. (A) Anti-HEV IgG seroprevalence rates in the general population dependent on the used
seroassay; (B) comparison of estimated seroprevalence rates adjusted for patient cohort. Patient cohorts
from left to right: general population, liver diseases, HIV infections, transplant recipients, swine/wild
animal contact (farmers, veterinarians, slaughterhouse workers, forestry workers); (C) calculated
anti-HEV seroprevalence in different European countries. Exact seroprevalence rates are displayed
in Table 3; and (D) amount of heterogeneity explained by used seroassay, study cohort, and
geographical location.
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Table 3. Calculated seroprevalence rates for the general population.
Title Abbott Adaltis Dia.Pro Mikrogen MP Other Wantai
Austria 1.9% * 0.7% * 6.6% * 8.9% * 3.9% * 9.3% * 13.9%
Belgium 4.5% * 2.5% * 10.9% * 13.8% * 7.4% * 14.3% 19.7% *
Czech Republic 1.5% * 0.5% * 5.9% 8.1% * 3.3% * 8.5% * 12.9% *
Denmark 4.8% * 2.8% * 11.4% * 14.3% * 7.8% * 15.2% 19.8%
France 12.0% * 8.7% 21.1% * 24.7% * 16.3% 25.4%* 31.9%
Germany 2.6% 1.1% * 7.8% * 10.3% 4.8% 10.8% 29.5%
Italy 0.1% * 0.1% * 2.4% 3.9% * 0.9% * 4.1% 7.5%*
Netherlands 1.8% 0.6% * 6.4% 8.7% * 3.7% 9.1% 27.0%
Spain 2.2% 0.9% * 7.1% 9.5% * 4.3% 10.0%* 14.7%
Switzerland 1.8% * 0.6%* 4.2% 8.8% 4.2% 9.2% 21,2%
UK 1.4% * 0.4% * 5.7% * 7.9% * 3.2% 8.3% * 12.7%
* For combinations of seroassays and countries for which reported seroprevalence rates were not determined,
the seroprevalence was calculated using a restricted maximum likelihood estimator model (R statistical platform
and The metafor Package).
3.3. Geographical Location
Studies included in the meta-analysis were from Germany (n = 15), France (n = 14), Spain (n = 11),
United Kingdom (n = 9), the Netherlands (n = 8), Italy (n = 6), Denmark (n = 3), Switzerland (n = 3),
Austria (n = 2), Belgium (n = 1), and the Czech Republic (n = 1). Independent of the assay employed,
there were large differences in calculated seroprevalence rates between countries (Figure 3C). In the
general population, the highest seroprevalence was estimated for France (WT 32% [95% confidence
interval 19–47] %; MP 16 [4–35] %) and the lowest for Italy (WT 8 [1–21] %; MP 1 [0–12] %) followed by
the UK (WT 13 [10–17] %; MP 3 [0–10] %). The calculated seroprevalence in France was significantly
higher than in the UK (p < 0.001) and Italy (p < 0.001; Figure 3C). The difference between the UK and
Italy was not significant (p > 0.05).
In addition to differences in seroprevalence between countries, differences in seroprevalence have
also been reported within countries. Such regional differences have best been described in France and
the UK. The highest anti-HEV seroprevalence rates (52.5%) throughout Europe were reported in the
Midi-Pyrénées region of Southwest France [18]. Although the Midi-Pyrénées region is relatively small
(45,348 km2, population 2,926,592), the anti-HEV IgG seroprevalence rate varies significantly within
different administrative areas within the region. For example, in a study employing the WT assay,
the seroprevalence in the Ariège area (4890 km2, population 152,366) was 71% compared to 23.2% in
Aveyron and Lot (13,952 km2, population 450,575) [24].
In general, a significantly higher seroprevalence was reported for the south when compared
to the north of France [25]. However, this difference failed to reach statistical significance when we
compared the pooled anti-HEV seroprevalence from regions in Southern France (Toulouse, Marseille,
Rhones-Alpes, regions of Languedoc-Roussillon, Rhone-Alpes, Midi-Pyrénées, Hyere) with the rest of
the country (p > 0.05).
A north/south gradient has also been described in the UK. The lowest seroprevalence in central
Europe was found in Scotland (WT 4%) [26] with a calculated seroprevalence of 13 [10–17] % (WT) in
the rest of the UK (north vs. south: p < 0.05).
3.4. Age and Gender
Forty-six of the 73 studies provided data on age. Most studies (n = 33) only provided the median
age of participants. Analysis of age was further complicated by the fact that studies evaluating whether
anti-HEV IgG seropositivity increases with age used age categories that were not consistent between
studies. Therefore, no detailed statistical analysis of the influence of age on anti-HEV seroprevalence
could be performed. However, of the 18 studies which were evaluable in terms of age all but one [27]
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showed that anti-HEV seroprevalence increases with age. Forty-five of the 73 studies provided
information on sex. No significant difference in HEV seroprevalence was found between genders.
3.5. Study Heterogeneity
Twenty-three percent of the observed heterogeneity in anti-HEV seroprevalence studies was due
to the assay employed and the geographical region, respectively. The study cohort accounted for
an additional 7% of the heterogeneity (Figure 3D). Thus, the majority of the observed heterogeneity
(52%) could be attributed to these three factors.
4. Discussion
The present study is the first meta-analysis of reported anti-HEV IgG seroprevalence rates in
Europe. Seventy-three articles compromising a total of 129,254 individuals were included. Published
seroprevalence rates ranged from 0.6% to 52.5%. Considerable heterogeneity was found between
studies that was mainly attributable to the anti-HEV IgG assay employed, the geographical location,
and the type of study cohort. Therefore, we calculated anti-HEV IgG seroprevalence depending on
geographical region, used seroassay, and studied population, which has, in our opinion, produced
a realistic overview of HEV seroprevalence in Europe and may allow a better interpretation of previous
and future studies on HEV seroprevalence in developing countries.
The majority of studies demonstrated a high exposure of the European population to HEV, which
contrasts with the relatively low (but increasing) number of reported hepatitis E cases in Europe.
This suggests that the majority of infections are asymptomatic and/or unrecognised [11,12]. Recently it
has been shown that locally-acquired infections with HEV genotype 3 tend to take a less severe course
than imported HEV infections [28].
The anti-HEV IgG assay employed had a significant influence on the reported seroprevalence
rates. Commercial assays vary considerably in their performance with a large range of sensitivities and
specificities [29,30]. Nine studies assessed seroprevalence rates in a given population using different
assays (Table 2), which resulted in very different seroprevalence rates depending on the employed
assay. For instance, Schnegg et al. found a seroprevalence of 4.9% in Swiss blood donors by using
the MP assay, while the seroprevalence in the same population was more than 5 times higher (21%)
when determined by the WT assay [31]. Compared to all the other assays, the anti-HEV IgG WT assay,
in general, produces higher seroprevalence estimates and has been regarded by many as the “gold
standard” in the field [32]. The reason for this is that it has a validated sensitivity for detecting distant
infection of 98% [33]. None of the other assays have been validated in this way and at least one other
commonly used assay has a sensitivity for detecting distant infection of < 50% [33]. However, the WT
assay is regarded by some observers as producing seroprevalence results that are so high that they
stretch biological plausibility and are simply a reflection of the assay’s poor specificity. In common
with all other commercial assays, the WT assay has not been fully assessed in terms of specificity for
distant infection. However, there are adult populations that have very low seroprevalence when the
WT assay is used. These include Fiji (2%) [34], New Zealand (4%) [35], and Scotland (4.6%) [26] and, in
the hyperendemic area of Southwest France, the seroprevalence is 2% in children aged 2–4 years [18].
Taken together, these data suggest that the WT IgG assay does not lack specificity in determining
previous infection. Furthermore, several studies have reported that a considerable number of blood
donors have HEV RNA at time of donations (Table 4), which lends weight to the notion that the WT
assay gives credible estimates of viral pressure on populations over time.
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Table 4. HEV viremia and seroprevalence in blood donors in European countries.





1:1438 (1:2200) ** Gallian et al., 2014 [15]
52.5% Mansuy et al., 2011 [18]
Germany
1:1200 Vollmer et al., 2012 [16]
1:4525 Baylis et al., 2012 [36]
29.5% Wenzel et al., 2013 [29]
The Netherlands 1:2671 27.0% Slot et al., 2013 [37]
England
1:2848 * Hewitt et al., 2014 [13]
1:7000 12.0% Ijaz et al., 2012 [38]
16.0% Beale et al., 2011 [39]
16.0% Dalton et al., 2008 [4]
Sweden 1:7986 NA Baylis et al., 2012 [36]
Austria 1:8416 13.5% Fischer et al., 2015 [40]
Scotland 1:14,520 4.7% Cleland et al., 2013 [35]
Seroprevalence studies have been restricted to those employing the highly-sensitive and partially-validated
Wantai anti-HEV IgG assay. HEV RNA was genotype 3 in all cases. * deconstructed solvent-detergent treated
mini-pools. NA: not available. ** Midi-Pyrénées/Méditerranées: 1:1438, France: 1:2200.
The current study suggests that, after accounting for differences in the employed assays anti-HEV
seroprevalence varies between countries, the highest anti-HEV IgG seroprevalence rates are found in
France and the lowest in Italy. An important route of infection for HEV is thought to be via the food
chain, due to consumption of HEV-infected pork products. Another possible route of infection is due
to environmental contamination with HEV. Interestingly, while France has the highest seroprevalence,
the country’s consumption of pork is less than in many other European countries (Table 5), as is the
number of pigs produced (Table 5 and Figure 4). It would appear that there is no clear relationship, at
least at the country level, between anti-HEV seroprevalence and either pork consumption or production
(Table 5). However, anti-HEV IgG seroprevalence may relate to differences in culinary practices
between countries/regions and/or different rates of viremia/viral loads of HEV-contaminated pork
products in the human food chain. In France, for example, HEV has been found to contaminate a range
of pork-based food delicacies, often at very high viral loads [41]. This includes figatellu, which is
a pork liver sausage commonly consumed in Southern France. Figatellu is meant to be consumed after
cooking, but is commonly eaten raw and has been implicated in a number of cases of locally-acquired
hepatitis E in Southern France [18,42].






















France 31.9 23,747 63.9 0.37 1931 30.2
Germany 29.5 58,628 80.6 0.72 4358 54.1
Denmark 19.8 19,108 5.6 3.41 352 62.9
Netherlands 27.0 14,014 16.8 0.83 640 38.1
Belgium 19.7 11,915 11.2 1.06 452 40.4
Spain 14.7 41,418 46.6 0.31 2363 50.7
Switzerland 13.8 No comparative data 8.1 NA 201 * 24.8
Austria 13.9 5417 8.5 0.64 474 55.8
Czech
Republic 12.9 2652 10.5 0.25 437 41.6
UK 12.7 10,299 64.1 0.16 1542 24.1
Italy 7.5 13,099 59.8 0.22 2451 41.0
NA = not available; * 2010 data: [43–46]; ** Product-moment correlation between HEV seroprevalence and
pig human/ratio r = 0.197 (p = 0.630); *** Product-moment correlation between HEV seroprevalence and pork
consumption r = 0.195 (p = 0.591).
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and less than 200 km apart, is of particular interest [24]. Such a huge difference in seropreval nce
is unlikely to be olely explained by diff rences in culinary culture in inhabitants of neighbouring areas
of Southe n Fr nce, and s ggest th t unknown environmental factors may hav a role as the source of
human inf ction. This hypothesis is lent furt er weight by the recent finding tha in Cor wall, UK
over 50% of patients presenting with hepatitis E lived within 2 km from the coast [47].
Despite the heterogeneity between studies, two themes have emerged: HEV seroprevalence is
higher in ndividuals exposed to s ine/wild animals and increases with age. The obse vatio that
anti-HEV seroprev ence is higher in i div du ls exposed to swine and wild animals further supports
the notion. C ntrary to the widely held v ew that most infections in Europe are caused by con m tion
of pork products contaminated with HEV [48], environmental fact rs may play an important role
in h an infection. The finding that anti-HEV IgG seropreval ce increases with age comes as no
surprise and is likely to refl t cumulative l fe-time exposure to HEV, which appears to b similar in
men and women.
Neverthel ss, the findi g that no significant difference in HEV seroprevalence was observed
between gender is somewhat surprising, since symptomatic HEV infection in developed countries is
much mor common in middle-aged a d elderly en [4,34]. Given that HEV exposure seems to be
unrelated to sex, we assu e that host f ctors must explain why th se populations are mor likely to
develop overt hepatitis.
We did not s ecifically study changes of seroprevalence over time due to the very limited number
of existing studie . It appears that, at least in the UK, Denmark, and Germany, seropre alence rates
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have fallen compared to 20 years ago [26,49–51]. There appears to be a cohort effect, related to date of
birth, suggesting that high seroprevalence rates seen in the elderly are due to a surge of infection in
the 1950s and 1960s. However, a study from the Netherlands has shown a recent dramatic increase
in seroprevalence in young adults [52]. This has been accompanied by an increase in viremic blood
donors from 1:2761 in 2011–2012 [37] to 1:600 in 2014 [14]. These data should be kept in mind when
interpreting Figure 3C, which displays the geographical variation in seroprevalence since, for unknown
reasons, HEV infection may have become hyperendemic in the Netherlands in recent years.
We chose to exclude seroprevalence studies prior to 2003 as we felt most were fundamentally
flawed. The reason for this is that such studies largely used “first generation” anti-HEV IgG assays
and produced seroprevalence estimates of < 5% due to very poor assay sensitivity, which previously
led us to the erroneous notion that HEV in Europe was uncommon and almost universally imported
from endemic developing countries [3].
Looking ahead, seroprevalence studies should consider seroprevalence at regional as well as
national level and attempt to minimize heterogeneity. This means that study cohorts need to be
uniformly delineated and the performance of assays employed at detecting distant infection need
to be accurately defined. For example, we currently do not know much about assay performance at
detecting distant infection in some important study cohorts such as immunosuppressed transplant
recipients, individuals with HIV, and patients with chronic liver disease. To this end studies are
currently in progress to determine the sensitivity and specificity of existing anti-HEV IgG assays at
detecting distant infection, together with a project to establish WHO reference materials for serological
assay development. The results are awaited with interest.
In conclusion, anti-HEV IgG seroprevalence rates in Europe ranged from 0.6% to 52.5%.
Considerable heterogeneity was found between studies, mainly attributable to the assay employed,
the geographical location and the type of study cohort. HEV seroprevalence varies both between
and within countries, is higher in individuals exposed to swine/wild animals and increases with age.
Future seroprevalence studies should minimize heterogeneity by defining assay performance and
study cohorts more accurately.
Supplementary Materials: The following are available online at www.mdpi.com/1999-4915/8/8/211/s1,
Table S1. Number of included studies per country; Table S2. All included studies and data extracted from
each study.
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